Literature DB >> 9364034

Procalcitonin in diagnosis of severe infections.

B Al-Nawas1, I Krammer, P M Shah.   

Abstract

Increased serum concentration of procalcitonin (PCT) in limited number of paediatric patients with acute severe bacterial infections has been described previously. In a prospective study in 337 hospitalised adult patients fulfilling the SIRS-criteria, serum PCT was determined on admission and up to 9 days thereafter. Patients with microbiologically documented infection showed peak values of 30 ng/ml at day 3, which rapidly decreased to normal levels. Patients without sepsis revealed baseline values (0.1 ng/ml or lower). The validity criteria were calculated for several breakpoints of PCT. We detected an interval from 0.1 to 0.5 ng/ml under which a severe microbial infection is unlikely (sensitivity 91%, specificity 25%, positive predictive value 39%, negative predictive value 86%). An infection is most likely above 0.5 ng/ml (sensitivity 60%, specificity 79%, positive predictive value 61%, negative predictive value 78%). Between these two points an infection can neither be confirmed nor excluded. The excellent specificity and negative predictive value at a cut-off point of 0.5 ng/ml suggests that this test might be a useful parameter in the management of infectious diseases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9364034

Source DB:  PubMed          Journal:  Eur J Med Res        ISSN: 0949-2321            Impact factor:   2.175


  45 in total

1.  Value of monitoring serum procalcitonin in neonates at risk of infection.

Authors:  M M Koskenvuo; K Irjala; A Kinnala; O Ruuskanen; P Kero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-05-16       Impact factor: 3.267

2.  Pre-emptive antibiotic treatment vs 'standard' treatment in patients with elevated serum procalcitonin levels after elective colorectal surgery: a prospective randomised pilot study.

Authors:  Ansgar Michael Chromik; Frank Endter; Waldemar Uhl; Arnulf Thiede; Hans Bernd Reith; Ulrich Mittelkötter
Journal:  Langenbecks Arch Surg       Date:  2005-12-21       Impact factor: 3.445

3.  Failure of PCT to indicate severe fungal infection in two immunodeficient patients.

Authors:  W Huber; U Schweigart; P Bottermann
Journal:  Infection       Date:  1997 Nov-Dec       Impact factor: 3.553

4.  Dynamic detection of N-terminal pro-B-type natriuretic peptide helps to predict the outcome of patients with major trauma.

Authors:  A Qian; M Zhang; G Zhao
Journal:  Eur J Trauma Emerg Surg       Date:  2014-06-03       Impact factor: 3.693

5.  Evaluation of serum C-reactive protein, procalcitonin, tumor necrosis factor alpha, and interleukin-10 levels as diagnostic and prognostic parameters in patients with community-acquired sepsis, severe sepsis, and septic shock.

Authors:  Y Heper; E H Akalin; R Mistik; S Akgöz; O Töre; G Göral; B Oral; F Budak; S Helvaci
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-08       Impact factor: 3.267

6.  Role of procalcitonin and granulocyte colony stimulating factor in the early prediction of infected necrosis in severe acute pancreatitis.

Authors:  C A Müller; W Uhl; G Printzen; B Gloor; H Bischofberger; O Tcholakov; M W Büchler
Journal:  Gut       Date:  2000-02       Impact factor: 23.059

7.  Usefulness of procalcitonin to differentiate typical from atypical community-acquired pneumonia.

Authors:  Matjaz Jereb; Tadeja Kotar
Journal:  Wien Klin Wochenschr       Date:  2006-04       Impact factor: 1.704

Review 8.  [Procalcitonin-based algorithm. Management of antibiotic therapy in critically ill patients].

Authors:  M Hochreiter; S Schroeder
Journal:  Anaesthesist       Date:  2011-07       Impact factor: 1.041

9.  Postoperative plasma concentrations of procalcitonin after different types of surgery.

Authors:  M Meisner; K Tschaikowsky; A Hutzler; C Schick; J Schüttler
Journal:  Intensive Care Med       Date:  1998-07       Impact factor: 17.440

10.  Usefulness of procalcitonin for diagnosis of infective endocarditis.

Authors:  Matjaz Jereb; Tadeja Kotar; Tomaz Jurca; Tatjana Lejko Zupanc
Journal:  Intern Emerg Med       Date:  2009-04-09       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.